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Abstract 
 
The survival of all microorganisms depends on the functionality of the 
enolpyruvyl transferase family of enzymes.  MurA (UDP-N-acetylglucosamine 
enolpyruvyl transferase, EC 2.5.1.7) and EPSPS (5-enolpyruvyl-shikimate-3-
phosahate synthase, EC 2.5.1.19) are the only known enzymes in this family.  MurA 
catalyzes the first committed step in the biosynthesis of cell wall peptidoglycan.  
EPSPS is the enzyme that catalyzes the sixth step of the shikimate pathway, leading 
to the synthesis of essential aromatic compounds found in plants, fungi and 
microorganisms.  Because both pathways are absent in mammals, enolpyruvyl 
transferases are attractive targets for the development of antimicrobial agents.  
While Escherichia coli and all other gram-negative bacteria possess only one 
copy of the MurA gene, analyses of the genomes of several gram-positive bacteria 
reveal the existence of two MurA genes, termed MurA1 and MurA2. For 
Streptomyces pneumoniae, it has been demonstrated that both MurA1 and MurA2, 
encode active enzymes.  Kinetic characterization of these enzymes failed, however, to 
demonstrate any significant difference between the two.  In addition, both are 
inhibited by the only naturally occurring antibiotic that inactivates MurA, fosfomycin.  
The research presented here focuses on the cloning, expression, purification and 
kinetic characterization of the MurA enzymes from two gram-positive pathogenic 
organisms: Staphylococcus aureus and Bacillus subtilis.   
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1. Introduction 
1.1. The Need for New Antibiotics 
According to the World Health Organization, infectious disease caused by 
bacterial pathogens continues to be a major cause of morbidity and mortality 
worldwide.  Pathogenic bacteria are linked to over 60% of the total deaths in 
underdeveloped countries and are the third leading cause of death throughout Europe.  
In industrialized countries, pathogens that were formerly found only in hospital 
environments are now being found in communal settings [1].  The majority of the 
bacterial species causing these infections have acquired resistance to one or more 
antibiotics. Antibiotic resistance can emerge rapidly, is highly adaptable and can 
progress through bacterial populations with relative ease. Pathogens can become 
resistant to antibiotics through modification of their own genes or acquisition of 
resistance genes from other bacteria [2, 3]. This ability to exchange genetic material 
across species and genera has resulted in the accumulation of multidrug-resistant 
phenotypes in species where infectious disease management is especially challenging.  
These species include methicillin-resistant Staphylococcus aureus, penicillin-resistant 
pneumoncoccus, vancomycin-resistant Enterococcus faecalis, and multidrug-resistant 
Acinetobacter baumannii and Pseudomonas aeruginosa [4].   
Advances in DNA sequencing technology have made it possible to elucidate an 
organism’s entire genome.  The availability of various bacterial genomic sequences 
gives us the opportunity to compare them at various levels and understand their 
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similarities and differences. These comparative genetics studies, in conjunction with 
structural and functional genomics, will provide valuable information for the 
generation and identification of novel drug products [5]. 
1.2. The Enolpyruvyl Transferase Family of Enzymes 
The survival of all microorganisms depends on the functionality of the 
enolpyruvyl transferase family of enzymes [6].  MurA (UDP-N-acetylglucosamine 
enolpyruvyl transferase, EC 2.5.1.7) and EPSPS (5-enolpyruvyl-shikimate-3-
phosahate synthase, EC 2.5.1.19) are the only known enzymes in this family.   MurA 
catalyzes the first committed step toward the biosynthesis of peptidoglycan, the main 
component of the bacterial cell wall [7, 8].  EPSPS catalyzes the sixth step of the 
shikimate pathway toward the synthesis of essential aromatic compounds found in 
plants, fungi and microorganisms [9-11]. Because both pathways are absent in 
mammals, enolpyruvyl transferases are attractive targets for the development of novel 
antimicrobial agents [6, 12, 13].  
1.2.1. Reactions Catalyzed by MurA 
The reactions catalyzed by the enolpyruvyl transferases proceed through the 
transfer of the enolpyruvyl moiety of phosphoenol pyruvate (PEP) to the hydroxyl 
group of a second substrate.  Unlike most PEP-dependent enzymes, which use PEP as 
a phosphoryl donor through the cleavage of the high-energy phosphorous oxygen 
bond, enolpyruvyl transferases cleave the carbon-oxygen bond of PEP to transfer the 
enolpyruvyl moiety to a second substrate releasing inorganic phosphate (Pi ) [14] .    
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MurA catalyzes the transfer of the enolpyruvyl moiety of PEP to UDP-N-
acetylglucosamine (UNAG) to form enolpyruvyl-UDP-N-acetylglucosamine (EP-
UNAG) and Pi (Fig. 1). EP-UNAG is a precursor of N-acetylmuramic acid, which 
alternates with N-acetylglucosamine to form the glycan chains that constitute the 
peptidoglycan layer of the cell wall [13, 15].   
1.2.2. Mechanism of Action of MurA 
MurA has received attention because it is the molecular target of the antibiotic 
fosfomycin [16-18]. Mechanistic and structural data for MurA show that the reaction 
follows an ordered mechanism in which UNAG interacts with free enzyme prior to 
the binding of PEP or inhibitor (Fig. 2).  The reaction pathway proceeds by the 
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Figure 1: The reaction catalyzed by MurA.   
Figure 2: The addition-elimination mechanism for MurA. 
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addition of a proton to PEP, yielding a PEP oxocarbenium ion.  The 3’-hydroxy group 
of UNAG is then deprotonated, resulting in a nucleophile that attacks the C-2 position 
of the oxocarbenium ion of PEP leading to a tetrahedral intermediate of the substrate 
[14, 19, 20]. A proton is then abstracted from the methyl group of the tetrahedral 
intermediate resulting in the formation of the vinyl ether product and Pi [20-23]. 
1.2.3. Catalytic Cycle of MurA 
The proposed catalytic cycle of the enolpyruvyl transferases, is shown in Fig. 3.  
E + S1 ↔ E S1 + S2 ↔ E S1 S2 ↔ EP1P2 → E + P1 + P2 
 
The free enzyme (E) reversibly binds the first substrate (S1), forming a binary 
complex (ES1) that undergoes a conformational change resulting in the formation of 
an active site for the second substrate.  The second substrate (S2), can then form a 
ternary complex (ES1S2) that is followed by the formation of two reaction products 
(EP1P2). Lastly, product release (E + P1 + P2) allows the enzyme to return to its 
original conformation [15, 24, 25].   
Following formation of the rapidly reversible MurA-UNAG complex, the loop 
region of MurA (residues 111-122), undergoes a conformational change that allows 
for the binding of PEP or fosfomycin in the active site [26, 27]. Fosfomycin inhibits 
MurA by forming an irreversible [15] covalent attachment with the thiol group of the 
Cys115 residue [19, 28-30] in the loop region preventing PEP from binding to the 
active site [22, 31]. Although fosfomycin covalently links to the thiol group of 
Figure 3: The catalytic cycle of MurA. 
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Cys115, it is not merely a group-specific reagent, because no other enzyme is known 
to be modified by this epoxide [16, 28, 30, 32].   
1.3. Purpose of Research 
Interference with cell wall biosynthesis is well-established as an excellent 
mechanism for killing both gram-positive and gram-negative bacteria, and enzymes 
of bacterial cell wall synthesis have historically been important targets for 
antibacterial agents [13, 23]. A series of enzymes, MurA to MurF, are required to 
synthesize peptidoglycan.  Inhibition of any one of these enzymes leads to cell lysis 
and death; however, aside from the inhibition of MurA by fosfomycin, enzymes in 
this pathway are not targeted by any known antibacterial agents [12, 13, 28, 33].  
While E. coli and all other gram-negative bacteria possess only one copy of the 
MurA gene, analysis of the genomes of several bacterial species revealed two copies 
of the MurA gene [34]. Found primarily in gram-positive bacteria exhibiting low-
G+C content, the duplicate genes were termed MurA1 and MurA2.  When compared 
to the protypical gram-negative MurA, the MurA1 sequence typically exhibits higher 
sequence conservation than the similarly-sized MurA2. Comparison to the structure 
of E. coli MurA shows that the major structural features and residues involved in 
ligand interactions are highly conserved, suggesting that it is unlikely that one of the 
genes is a nonfunctional copy. 
In the gram-positive bacteria Streptomyces pneumoniae, it was demonstrated that 
the MurA1 and MurA2 genes encode two active enzymes that are neither close to 
 16
each other in the genome nor clustered with any other peptidoglycan synthesis 
enzymes [34].  Kinetic characterization of both enzymes, however, failed to 
demonstrate any significant differences between the two, and both are inhibited by 
fosfomycin.  This suggests that both enzymes are active tranferases, able to catalyze 
the transfer of enolpyruvate from PEP to UNAG. In addition, gene knockout 
experiments revealed that single deletions of either gene did not cause a loss of 
viability, but deletion of both genes was lethal. Therefore, it is critical that a novel 
MurA inhibitor possess inhibitory activity against both MurA1 and MurA2 to ensure 
antibacterial activity against gram-positive cocci [6]. 
To design new antibiotics, we need to improve our knowledge of the structural 
and functional genomics of pathogenic bacteria.  To date, little information is known 
about the pair of MurA enzymes found in many gram-positive bacterial pathogens. 
The research presented here focuses on the expression, purification and kinetic 
characterization of the MurA enzymes from two such organisms: Staphylococcus 
aureus and Bacillus subtilis. 
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2. Materials and Methods 
2.1. General Materials 
2.1.1. Competent Cells 
Competent cell strains used were: One Shot® BL21(DE3) (Invitrogen, Carlsbad, 
CA), BL21(DE3)pLysS (Invitrogen), BL21-CodonPlus(DE3)-RIL (Stratagene, La 
Jolla, CA), ArcticExpress(DE3) (Stratagene) and DH5α (Invitrogen). 
2.1.2. Chemicals and Equipment 
A Labconco Water Pure Plus System was used to purify all H2O used for 
research.  All chemicals and equipment were purchased from Sigma (St. Louis, MO) 
or Fisher (Springfield, NJ) unless otherwise noted. 
2.1.3. Solutions 
2.1.3.1. Media 
All media was autoclaved and stored at 4 ˚C.  Antibiotic stocks were added to the 
media prior to use.  
LB Media: 
10 g tryptone 
7.5 g yeast extract 
5 g NaCl 
Fill to 1 L with H2O  
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LB Agar: 
20 g granulated agar 
Fill to 1 L with LB media 
To prepare plates, the agar was heated in the microwave until liquid and then 
allowed to cool to roughly 30 °C before antibiotic stocks were added. The LB-
antibiotic agar was then poured into the desired number of Petri dishes in a Laminar 
flow hood. 
2.1.3.2. Antibiotics 
Ampicillin stocks at 100 mg/ml in H2O, gentamycin stocks at 20 mg/ml in H2O 
and chloramphenical stocks at 25 mg/ml in EtOH were sterile filtered with a 0.45 μm 
filter and stored at -20 ˚C.  Amp and Gm  stocks were diluted 1 : 1000 (final [Amp] = 
100 µg/ml; final [35] = 20 µg/ml) and Cm stocks were diluted 1 : 2000 (final [Cm] = 
12.5 µg/ml) for all purposes. 
2.1.3.3. DNA Electrophoresis 
A 50X concentrated solution of TAE was stored at room temperature and diluted 
to 1X prior to use.  The following protocol was used to prepare the DNA gel: 500 mg 
of agarose was heated in 50 ml of 1X TAE until dissolved, 1 μl of ethidium bromide 
(5 mg/ml) was added to the solution and the gel was cast using a DNA mini-
submarine gel electrophoresis unit (GE Healthcare, Piscataway, NJ). The DNA was 
visualized with UV light following electrophoresis. 
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50X TAE: 
242 g Tris (pH 8.5) 
57.1 ml glacial acetic acid 
100 ml 0.5 M EDTA (pH 8.0) 
Fill to 1 L with H2O 
Molecular ladder was prepared by adding 5 μl DNA marker (Cambrex Bio 
Science, Rockland, ME) and 2 μl 10X Bluejuice (Invitrogen) to 3 μl H2O.  The DNA 
ladder corresponded to 10, 7, 5, 4, 3, 2.5, 2, 1.5 and 1 Kb markers. 
2.1.3.4. SDS Electrophoresis 
Running buffer was prepared as a 10X concentrated solution and diluted to 1X 
prior to use.  Coomassie stain was filtered with a Whatman 5 filter and stored in a 
dark bottle.  Acrylamide/Bis Solution, 30% 19:1 crosslinker ratio (Biorad, Hercules, 
CA), APS, TEMED (Biorad) and Tris buffers were stored at 4 ˚C.  All other solutions 
were stored at room temperature.  SDS-PAGE gels were made according to the 
following protocol and stored at 4 ˚C for up to 2 weeks. The resolving portion of the 
gel was cast and allowed to solidify before casting the stacking portion.  Gels were 
stained for a minimum of 15 minutes and destained for several hours in the solutions 
listed below. 
Resolving Portion SDS gel: (1 gel) 
4 ml 30 % Acrylamide/Bis solution 
100 μl 10 % (w/v) SDS 
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2.5 ml 1.5 M Tris (pH 8.8) 
3.36 ml H2O 
80 μl 10 % (w/v) APS 
10.0 μl TEMED  
Stacking  Portion SDS gel: (1 gel) 
650 μl 30 % Acrylamide/Bis solution 
50 μl 10 % SDS 
1.25 ml 0.5 M Tris (pH 6.8) 
3.05 ml H2O 
40 μl 10 % APS 
5 μl TEMED  
10X SDS Running Buffer: 
30 g Tris (pH 8.5) 
144 g glycine 
10 g SDS 
Fill to 1 L with H2O 
Coomassie Stain: 
1.25 g Coomassie brilliant blue R-250 
500 ml 95 % EtOH 
450 ml H2O 
50 ml 100 % acetic acid 
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Destain: 
500 ml EtOH 
100 ml acetic acid  
400 ml H2O 
5X Loading Buffer: 
1.82 g Tris (pH 8.5) 
5 g SDS  
12.5 ml β-mercaptoethanol 
25 ml glycerol 
1.28 ml HCl 
0.028 g bromophenol blue 
Fill to 50 ml with H2O 
SDS Low Range Marker: 
Marker was prepared by adding 50 μl concentrated marker (Biorad) and 100 μl 
5X loading dye to 350 μl H2O and heating the solution for 5 min at 100 ˚C.  Marker 
was stored at -20 ˚C.  The molecular weights in the marker corresponded to 97.4, 
66.2, 45, 31, 21.5 and 14.4 kD.   
2.1.3.5. FPLC Buffers 
All buffers for protein purification were prepared using purified H2O cooled to  
4 oC.  Following filtration with a 0.45 μm filter, the pH was adjusted with 12 N HCl 
and the buffers were stored at 4 ˚C. 
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Buffer A: 
50 mM Tris (pH 7.8) 
2.5 mM DTT 
1 mM EDTA 
Buffer A + 1.0 M NaCl: 
50 mM Tris (pH 7.8) 
1.0 M NaCl 
2.5 mM DTT 
1 mM EDTA 
Buffer A + Glutathione: 
50 mM Tris (pH 7.8) 
10 mM reduced glutathione 
2.5 mM DTT 
1 mM EDTA 
Extraction Buffer: 
50 mM Tris (pH 7.8) 
2.5 mM DTT 
1 mM EDTA 
0.1 % (v/v) Tween 20 
PreScission Buffer A: 
50 mM HEPES (pH 8.0) 
150 mM NaCl 
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2 mM DTT 
1 mM EDTA 
PreScission Buffer A + Glutathione 
50 mM HEPES (pH 8.0) 
150 mM NaCl 
2 mM DTT 
1 mM EDTA 
10 mM reduced glutathione 
2.2. General Methods 
2.2.1. Preparation of Competent Cells 
Commercially available competent cells were used to make lab stocks of new 
CaCl2 competent cells.  BL21(DE3) and DH5α cells were grown in media containing 
no antibiotic, PLysS(DE3) and RIL(DE3) cells were grown in media containing 
chloramphical and ArcticExpress(DE3) cells were grown in media containing 
gentamycin. A Beckman J2-21 centrifuge programmed to spin for 10 min at 6,000 
rpm and 4 ˚C was used for all centrifugation steps. All cells were incubated at 37 oC 
while shaking at 250 rpm. Overnight cultures were grown in 5 ml LB media and then 
transferred to 250 ml LB media. Upon reaching an OD600 of 0.5 - 0.7, the cells were 
harvested by centrifugation.  The supernatant was decanted and the pellets were 
washed with 100 ml of sterile 0.1 M MgCl2 and then the cells were harvested by 
centrifugation.  The supernatant was decanted and the pellets were resuspended in 
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100 ml of sterile 0.1 M CaCl2.  The resuspended solution was incubated on ice for 20 
min and then the cells were harvested by centrifugation.  The supernatant was 
decanted and the cells were resuspended in 20 ml of sterile 0.1 M CaCl2.  Following 
resuspension, the cells were incubated for 30 min on ice before 5 ml of sterile 50 % 
(v/v) glycerol was added.  The cells were aliquoted into microcentrifuge tubes and 
stored at -80 ˚C.   
2.2.2. Transformations 
Competent cells were transformed by adding 50 to 250 ng of plasmid to 100 μl of  
cells.  This mixture was incubated on ice for 30 min, heat-shocked for 45 sec at 42 ˚C 
and incubated again on ice for 2 min.  After adding 900 μl of LB media, the mixture 
was incubated 1 h at 37 °C while shaking at 250 rpm.  The cells were then 
centrifuged for 30 sec at 13,000 rpm using an Eppendorf 5417C centrifuge and 900 μl 
of supernatant was removed.  The pellet was resuspended in the remaining broth, 
plated on LB agar plates containing the appropriate antibiotic and incubated overnight 
at 37 ˚C.   
2.2.3. Plasmid Preparations 
Plasmids were isolated and purified using the Mini-Prep kit (Qiagen, Valencia, 
CA), according to the specified protocol. DNA was eluted in 40 µl sterile H2O. 
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2.2.4. DNA Electrophoresis 
All DNA samples were prepared by adding 2 μl of 10X Bluejuice and 2 μl of 
DNA (50 - 250 ng) to 6 µl of H2O.  Electrophoresis of gels was performed at 120 mV 
for 45 min.  
2.2.5. Sequencing 
DNA sequences were determined using commercially available pGEX vector 
primers (GE Healthcare) at the University of Kansas Medical Center’s biotech 
research support facility using a PE Biosystems Prism 377XL sequencer (Applied 
Biosystems, Foster City, CA). 
2.2.6. Induction Studies 
 The positively sequenced plasmids of S. aureus and B. subtilis MurA1 and 
MurA2 were separately transformed into BL21(DE3), ArcticExpress(DE3), 
pLysS(DE3) and RIL(DE3) competent cell lines to look for soluble over-expression.  
All cell lines were analyzed by choosing three separate colonies from each 
transformation plate and incubating them individually in 5 ml LB-Amp media 
overnight at 37 °C and 250 rpm.  The appropriate cell antibiotics (2.1.3.2) were 
included in the ArcticExpress(DE3), pLysS(DE3) and RIL(DE3) overnights. A 50 μl 
aliquot of the overnight culture was used to inoculate 5 ml of fresh LB-antibiotic 
media, and the culture was incubated at 37 ˚C while shaking at 250 rpm. After 
reaching an OD600 of 0.4 - 0.6, the temperature of the culture was lowered to 18 oC 
and a 1 ml aliquot was removed to serve as a control.  Incubation continued for 20 - 
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30 min and then the cells were induced with IPTG to a final concentration of 0.5 mM. 
After induction, cells were incubated for 25 - 27 h at 18 ˚C while shaking at 250 rpm.  
A 1 ml aliquot was removed and all aliquots were centrifuged at 13,000 rpm for 1 
min using an Eppendorf 5417C centrifuge. Following the removal of the supernatant, 
each pellet was resuspended with 200 µl extraction buffer and sonicated on ice 
(settings: duty cycle 100%, micro tip 4, pulsed sonication) for 2 x 20 s.  Following 
sonication, the induced pellet solution was centrifuged for 1 min at 13,000 rpm and 
the supernatant (soluble protein) was transferred to a microcentrifuge tube.  The pellet 
(cell debris and insoluble protein) was resuspended in 200 µl of extraction buffer.  
The control, supernatant, and pellet samples were mixed with 50 µl 5X loading dye, 
vortexed briefly, and heated for 5 min at 100 °C.  The levels of over-expression were 
visualized with SDS-PAGE.  In an attempt to increase the amount of soluble protein, 
the induction studies were repeated with adjustments to the time and temperature of 
incubation, the cell density at the time of induction and the final concentration of 
IPTG.   
2.2.7. Glycerol Stocks 
A 900 μl aliquot of an overnight cell culture was mixed with 160 μl 50% 
glycerol and stored at -80 oC for use in future experiments. 
2.2.8. SDS Electrophoresis 
All SDS-PAGE samples were prepared by adding 10 µl 5X loading buffer to 
40 µl sample. The samples were heated for 5 min at 100 ˚C, and were loaded onto the 
 27
gel by pipeting 15-20 μl into each lane.  Electrophoresis of gels was performed using 
a mini PROTEAN® 3 cell  (Biorad) at 160 V for 1 h.  
2.2.9. Determination of Protein Concentration 
Protein concentration was determined using Coomassie reagent (Pierce, Rockford, 
IL) according to the Bradford method [36].  The standards and unknowns were 
prepared using the following protocol: 1.7 μl of protein was added to 31.7 μl H2O and 
300 μl Coomassie reagent in a 96-well plate and the absorbance was measured at 596 
nm using a SpectraMax 340PC plate reader.  The UV absorption of each unknown 
was fit to a BSA standard curve at concentrations of 0.5, 1.0, 1.5 and 2.0 mg/ml to 
determine the protein concentration.   
2.3. E. cloacae MurA and E. coli MurB 
To measure enzymatic activity, the MurA - MurB coupled assay was utilized [37]. 
The coupled reaction is started by MurA converting UNAG and PEP to enolpyruvyl-
UNAG (EP-UNAG), which is subsequently reduced to UDP-N-acetylmuramic acid 
(UNAM) by MurB, using one equivalent of NADPH (Fig. 4).  To compensate for the 
diaphorase activity of MurB, a glucose oxidase (GOX)/glucose system was exploited, 
resulting in a stable base line 
prior to initiation of the 
MurA reaction.   
UNAG +  PEP
NADPH    NADP+
MurA
Pi
MurBEP-UNAG UNAG-Mur
Figure 4: MurA-MurB coupled assay. 
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2.3.1. DNA 
E. cloacae MurA in a pET-9d vector was provided by Dr. Ernst Schönbrunn. E. 
coli MurB in a pGEX-5X-1 GST fusion vector was provided by Dr. Florian Krekel. 
2.4. S. aureus and B. subtilis MurA 
2.4.1. DNA   
The pGEX-6P-1 vector containing tac promoter was purchased from GE 
Healthcare. This particular vector was chosen to enhance solubility of the protein as 
well as simplifying the purification due to the GST tag.  The S. aureus MurA1 and the 
B. subtilis MurA1 and MurA2 genes were provided by Scott Crupper. The S. aureus 
MurA2 gene was synthesized in the pGEX-6P-1 vector by GeneArt (Regensburg , 
Germany).   
2.4.2. Primers  
All primers for cloning were synthesized by MWG Biotech AG (High Point, NC), 
diluted to 100 pmol/μl with H2O and stored at -20 ˚C.  All primers are written in the 
5' to 3' direction with the altered codon or the restriction sites used for restriction 
digests underlined.   
 
S. aureus MurA1: 
S33L #1- CCAATATTGACAGCATCTTTATTAGCTTCTGATAAACCGAGTAAATTAG 
S33L #2- CTAATTTACTCGGTTTATCAGAAGCTAATAAAGATGCTGTCAATATTGG 
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I335F #1- 
CCGAAACTGTTTTTGAAAACCGTTTTATGCATGTTGCAGAGTTCAAACG 
 
I335F #2- 
CGTTTGAACTCTGCAACATGCATAAAACGGTTTTCAAAAACAGTTTCGG 
 
 
B. subtilis MurA1: 
 
BamH I- ATACGCGGATCCATGGAAAAAATCATCGTCCGCGGC 
 
Not I- GTCGTTTCTGACTTAAATGCATAAGCGGCCGCAAAAGGAAAA 
 
 
B. subtilis MurA2: 
 
EcoR I- ATACCGGAATTCATGGAAAAGTTGAATATTGCCGGCGGTGACTCGTT 
 
Not I- GAACAGCTTCAAAATTCATAAGCGGCCGCTAAACTATGGCCGGCCG 
 
A374S #1- GCGTGCCGGATCCTGCTTGGTGGTAGCCGG  
 
A374S #2- CCGGCTACCACCAAGCAGGATCCGGCACGC 
 
2.4.3. Polymerase Chain Reaction 
The B. subtilis DNA and primers were used to set up PCR and restriction digest 
sites to ligate the genes into the pGEX-6P-1 vector.  All reagents for PCR were from 
the Failsafe PCR kit (Epicenter, Madison, WI).  The PCR mixture contained the 
following: 46 μl H2O, 1 μl (2 - 10 ng) DNA template, 1 μl (100 pmol/μl) of each 
primer, 1 μl enzyme mix and 50 μl buffer B.  The reaction was prepared on ice and 
divided into two tubes that were then placed in an Eppendorf Mastercycler, set for an 
initial denaturing period at 95 °C for 4 min.  A cycle of denaturation at 95 °C for 45 s, 
annealing at 67 °C for 45 s and elongation at 72 °C for 2.5 min was repeated 33 
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times.  The thermocycler was programmed to hold at 4 °C indefinitely following the 
completed program.  After PCR was completed, 10 µl of 10X Bluejuice was added to 
each tube and the total volume of the sample was loaded onto an agarose gel. 
2.4.4. Gel Extractions 
Gel extractions were performed on the PCR products using a Gel-Extraction kit 
(Qiagen), according to the specified protocol. 
2.4.5. Restriction Digests 
All enzymes and buffers for restriction digests were purchased from New England 
Biolabs (Beverly, MA).  Single site restriction digests were performed on the PCR 
products and pGEX vectors using the following protocol: 4 μl H2O, 5 μl buffer (EcoR 
I buffer for B. subtilis MurA1 and buffer 3 for B. subtilis MurA2), 0.5 μL BSA (1 
mg/ml), 1 μl (10 U) Not I, and 40 μl (1 - 5 μg) PCR product or vector.  These digests 
were incubated for 16 h at 37 °C.  The DNA was then purified by the QIAquick PCR 
Purification kit (Qiagen), according to the accompanying literature. DNA was eluted 
in 40 µl H2O. A second single site restriction digest for the PCR products and vectors 
was set up following the same protocol, except that 1 μl (20 U) BamH I or 1 μl (20 
U) EcoR I  was used in place of Not I. These digests were incubated for 4 h at 37 oC. 
The DNA was then purified by the QIAquick PCR Purification kit and eluted in 40 µl 
H2O. 
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2.4.6. Ligations 
All enzymes and buffers for ligation were purchased from New England Biolabs.  
The digested PCR products of B. subtilis MurA1 and MurA2, were ligated into the p-
GEX-6P-1 vector.   Ligations were set up using a 4:1 insert:vector size ratio by 
adding 4 μl (100 ng) PCR product, 10 μl H2O, 2 μl 10X ligation buffer, 3 μL (100 ng) 
digested vector and 2 μl (800 U) ligase to a microcentrifuge tube and incubating the 
reaction for 16 h at 19 °C.  The ligation products were transformed into BL21(DE3) 
competent cells and several colonies were selected for plasmid preparations.  
Restriction digests of the new construct were performed using the restriction digest 
protocol described previously (2.4.5) to verify the size of the inserted gene.  The 
sequence of the new construct was verified by sequencing. 
2.4.7. Site-Directed Mutagenesis 
Site-directed mutagenesis of S. aureus MurA1 and B. subtilis MurA2 were 
performed to correct mutations introduced in the cloning process using the Qwik  
ChangeII Site-directed Mutagenesis kit (Stratagene).  The desired mutation was made 
to the DNA using PCR and the following protocol:  38.6 μl H2O, 5 μl 10X reaction 
buffer, 2 μl (25 - 50 ng)  DNA, 1.7 μl (125 ng) of each primer, 1 μl dNTP mix, and 1 
μl polymerase was mixed on ice.  The reaction was placed in an Eppendorf 
Mastercycler set for an initial denaturing period at 95 °C for 30 s.  A cycle of 
denaturation at 95 °C for 30 s, annealing at 55 °C for 1 min and elongation at 68 °C 
for 15 min was repeated 30 times.  The thermocycler was programmed to hold at 4 °C 
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indefinitely following the completed program. To remove vector that had not been 
mutated, 1 μl of DpnI was incubated with the reaction mixture for 2 h at 37 ˚C and 
then stored at -20 ˚C.  Following PCR, the products were transformed into DH5α 
competent cells and several colonies were selected for plasmid preparations.  The 
corrected mutation was verified by DNA sequencing. 
2.4.8. Over-expression of MurA 
Over-expression of the MurA-GST fusion proteins was carried out using the 
following protocol:  An overnight culture was prepared in which 50 μl of the 
RIL(DE3) cell glycerol stock was added to 50 ml of LB-Amp-Cm media and 
incubated overnight at 37 °C while shaking at 250 rpm.  A 7 ml aliquot of the 
overnight culture was added to each of 6 flasks containing 670 ml  LB-Amp-Cm 
media and 1 drop of antifoam.  These cultures were incubated at 37 °C while shaking 
at 200 rpm until reaching an OD600 of 0.4 - 0.6. The temperature of the culture was 
then lowered to 18 oC and incubation continued for 20 - 30 min before the cells were 
induced with IPTG to a final concentration of 0.5 mM. After induction, cells were 
incubated for 25 - 27 h at 18 ˚C while shaking at 200 rpm before being centrifuged 
for 10 min at 4 ˚C  and 6,000 rpm using a Beckman J2-21 centrifuge.  The 
supernatant was discarded, the cell pellets were collected, massed and frozen at -80 
°C. 
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2.4.9. Purification of MurA 
The MurA-GST fusion proteins were purified at 4 °C using an ÄKTA FPLC 
system (GE Healthcare).  Cells pellets were suspended in 10 ml extraction buffer per 
1 g of cells plus 1 mg lysozyme per 1 g of cells by stirring for 2 h at 4 °C.  The 
solution was sonicated (settings: duty cycle 100%, micro tip 3, pulsed sonication) on 
ice for 2 x 30 sec and centrifuged for 60 min at 4 oC and 18,000 rpm using a Beckman 
J2-21 centrifuge.  The supernatant was collected and was loaded onto a 40 ml 
GSTPrep FF 16/10 column (GE Healthcare) that had been pre-equilibrated with 
buffer A.  The column was washed with 10 CV buffer A to wash out unbound protein 
and MurA was eluted using a single step-gradient to 100 % buffer A + glutathione.  
The fractions were analyzed for the MurA-GST fusion protein by SDS-PAGE.  
Fractions containing the fusion protein were digested with PreScission protease in a 
1:25 (mg:mg) ratio of protease to MurA for 4 h at 4 oC while concentrating in an 
Amicon device with a 30 kD filter (Millipore, Bedford, MA). This protein solution 
was subjected to a second purification step using a 20 ml HiLoad 16/10 Q Sepharose 
FF column (GE Healthcare) or a 6 mL Resourse Q column (GE Healthcare).  The 
HiLoad Q-Seph was used for both MurA1 enzymes due to a high amount of protein 
(150 – 200 mg) being purified.  The Resource Q was used for both MurA2 enzymes 
due to a limited amount of protein (10 – 15 mg) being purified. The protein was 
applied to the column which had previously been equilibrated with buffer A.  The 
protein was eluted from the column by increasing the salt concentration in the mobile 
phase via a gradient from buffer A to buffer A + 1.0 M NaCl from 0% to 40% over 10 
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CV. The gradient was then increased from 40% to 100% over 2 CV with an added 
wash of 100% buffer A + 1.0 M NaCl for 3 CV. Fractions were assayed for protein 
content using SDS-PAGE and were desalted and concentrated to less than 20 ml 
using an Amicon device and Millipore 30 kD filter.  Desalting was accomplished by 
adding buffer A until the salinity readings on a Corning Checkmate II conductivity 
meter were less than 10 µS/cm2. After concentration, the fractions were aliquoted into 
2 ml microcentrifuge tubes and stored at -80 oC. 
2.4.10. Kinetic Analysis of MurA 
Kinetic analysis of MurA using a continuous assay requires coupling to MurB, 
which utilizes the product EP-UNAG to form UNAG-Mur while consuming NADPH. 
Control samples with no MurA were used to account for a decrease in absorbance due 
to oxidation of NADPH.  The change in NADPH absorbance was recorded at 340 nm 
in a 96-well plate using a SpectraMax 340PC plate reader. Enzyme activity is 
expressed as mmol product / min of reaction / mg of MurA (U/mg). Data evaluation 
was performed with SigmaPlot (SPSS Science, Chicago, IL, USA). 
The kinetic analysis of the MurA enzymes was carried out in 250 µl of 50 mM 
HEPES (pH 8.0) + 2 mM DTT at 25 oC using the MurA - MurB coupled assay.  All 
assays were performed with a final concentration of 50 mM KCl, 20 mM glucose, 20 
U GOX, 0.3 mM NADPH, 20 µg MurB and enzyme concentrations that were 
dependent on the activity and availability of each enzyme: 0.01 mg E. cloacae MurA, 
0.3 mg S. aureus and B. subtilis MurA1, 0.02 mg S. aureus MurA2, and 0.2 mg B. 
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subtilis MurA2. Assays to determine the Km values were performed with saturating 
amounts of the first substrate (6 mM UNAG or 4 mM PEP) and increasing 
concentrations (0.1 – 3.0 mM) of the second substrate. All assays were started by 
addition of the saturating substrate. The Km values were determined by fitting the 
kinetic data to equation 1 
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where v is the initial velocity, Vmax is the maximum velocity, Km is the Michaelis 
constant and [S] is the substrate concentration (UNAG or PEP) being varied.   
Assays to determine the IC50 values were performed for E. cloacae MurA, S. 
aureus and B. subtilis MurA1 using final concentrations of 1 mM UNAG, 1 mM PEP 
and increasing concentrations (0.1 – 1000 µM) of fosfomycin. Assays to determine 
the IC50 values for S. aureus and B. subtilis MurA2 were performed with the Km value 
for UNAG (43 µM), 1 mM PEP and increasing concentrations (0.1 – 1000 µM) of 
fosfomycin.  All assays were started with the addition of PEP following a 15 min 
incubation period. IC50 values were determined by fitting the data to equation 2 
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where v is the initial velocity, Vmax is the maximum velocity, Vmin is the minimum 
velocity, [I] is the concentration of inhibitor and n is the hill slope. 
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The pH profile of the S. aureus and B. subtilis MurA enzymes was examined and 
compared to E. cloacae MurA. Assays were performed in 250 µl of 50 mM MES (pH 
6.0) + 2 mM DTT, 50 mM MOPS (pH 7.0) + 2 mM DTT, 50 mM HEPES (pH 8.0) + 
2 mM DTT and 50 mM TAPS (pH 9.0) + 2 mM DTT at 25 oC using the MurA - 
MurB coupled assay.  All assays were performed with a final concentration of 50 mM 
KCl, 20 mM glucose, 20 U GOX, 0.3 mM NADPH, 20 µg MurB, 1 mM UNAG, 
1mM PEP and the same enzyme concentrations that were used for the kinetic 
analysis. All pH profile assays were started by addition of PEP. 
The effect of specific cations and anions on the activity of S. aureus and B. 
subtilis MurA enzymes was examined and compared to E. cloacae MurA. Assays 
were performed  in 250 µl of 50 mM HEPES (pH 8.0) + 2 mM DTT at 25 oC using 
the MurA - MurB coupled assay.  All assays were performed with a final 
concentration of  20 mM glucose, 20 U GOX, 0.3 mM NADPH, 20 µg MurB, 1 mM 
UNAG, 1 mM PEP and the same enzyme concentrations that were used for the 
kinetic analysis. Three concentrations (50 mM, 100 mM, 250 mM) of the following 
salts were used to test each enzyme: CaCl, KCl, NaCl, NH4Cl, Ca(CH3CO2)2, 
KCH3CO2, NaCH3CO2, NH4CH3CO2, Na2SO4 and (NH4)2SO4. All ionic-dependence 
assays were started by addition of PEP. 
The effect of detergents and organic solvents on the activity of S. aureus and B. 
subtilis MurA enzymes was examined and compared to E. cloacae MurA. Buffer 
solutions were prepared containing 50 mM HEPES (pH 8.0) + 2 mM DTT  and 5 % 
and 10 % (v/v) of the following solutions: DMSO, EtOH, Triton X-100, glycerol, and 
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n-Octyl-β-D-glucoside. Assays were performed in 250 µl of each buffer at 25 oC 
using the MurA - MurB coupled assay.  All assays were performed with a final 
concentration of  50 mM KCl, 20 mM glucose, 20 U GOX, 0.3 mM NADPH, 20 µg 
MurB, 1 mM UNAG, 1 mM PEP and the same enzyme concentrations that were used 
for the kinetic analysis. All detergent and solvent assays were started by addition of 
PEP. 
2.5. PreScission Protease 
2.5.1. DNA 
PreScission protease was provided by Dr. Ernst Schönbrunn. 
2.5.2. Over-expression of PreScission  
Over-expression of the PreScission-GST fusion protein was carried out using the 
following protocol: an overnight culture was prepared in which 50 μl of the glycerol 
stock in pLysS(DE3) cells was added to 50 ml of LB-Cm media and incubated 
overnight at 37 °C while shaking at 250 rpm.  A 7 ml aliquot of the overnight culture 
was added to each of 6 flasks containing 670 ml  LB-Cm media and 1 drop of 
antifoam.  These cultures were incubated at 37 °C while shaking at 200 rpm until an 
OD600 of 0.9 – 1.1 was reached.  The cells were induced with IPTG to a final 
concentration of 0.3 mM, and were allowed to grow for 4 - 5 h at 37 ˚C while shaking 
at 200 rpm before being centrifuged for 10 min at 4 °C and 6,000 rpm using a 
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Beckman J2-21 centrifuge.  The supernatant was discarded, the cell pellets were 
collected, massed and frozen at -80 °C. 
2.5.3. Purification of PreScission  
The PreScission-GST fusion protein was purified at 4 °C using an ÄKTA FPLC 
system.  Cells pellets were suspended in 10 ml PreScission buffer A + 0.1 % Tween 
20 per 1 g of cells plus 1 mg lysozyme per 1 g of cells by stirring for 2 h at 4 °C.  The 
solution was sonicated (settings: duty cycle 100%, micro tip 3, pulsed sonication) on 
ice for 2 x 30 sec and centrifuged for 60 min at 4 oC and 18,000 rpm using a Beckman 
J2-21 centrifuge.  The supernatant was collected and was loaded onto a 40 ml 
GSTPrep FF 16/10 column that had been pre-equilibrated with PreScission buffer A.  
The column was washed with 10 CV PreScission buffer A to wash out unbound 
protein and PreScission was eluted using a single step-gradient to 100 % PreScission 
buffer A + glutathione.  The fractions were analyzed for the PreScission-GST fusion 
protein by SDS-PAGE.  Fractions containing the fusion protein were concentrated to 
less than 20 ml using an Amicon device with a 30kD filter. After concentration,  20 % 
(v/v) glycerol was added and the fractions were aliquoted into microcentrifuge tubes 
and stored at -80 oC. 
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3. Results and Discussion 
 
3.1. Molecular Alignments of Pathogenic Bacteria 
Sequence alignment is a tool that can be 
used to identify regions of similarity in 
genetic material. In protein sequences, the 
degree of similarity between amino acids 
occupying a particular position can be 
interpreted as a rough measure of how 
conserved a region is among lineages. The 
absence of substitutions in a particular 
region, or the presence of only very 
conservative substitutions, suggests that this 
region has structural or functional 
importance. Global alignments (similarity matrix PAM250) of MurA from several 
pathogenic bacteria reveal approximately 50 % identity and 70 % similarity (Table 1) 
to E. cloacae MurA.  Similar values are also found when aligning the two MurA 
genes from the same species. The sequence alignments of E. cloacae MurA versus S. 
aureus and B. subtilis MurA1 and MurA2 are shown in Table 2. Since fosfomycin 
inhibits E. cloacae MurA by forming a covalent bond with the active site residue 
Cys115, we can speculate whether the S. aureus or B. subtilis MurA will be inhibited 
Table 1: Identity and similarity of MurA from 
pathogenic bacteria to E. Cloacae MurA. 
 
Organism Identity/Similarity to E. cloacae MurA 
MurA1 49% / 72% Staphylococcus 
aureus MurA2 42% / 68% 
MurA1 48% / 71% Bacillus 
subtilis MurA2 45% / 69% 
MurA1 50% / 69% Streptococcus 
pneumoniae MurA2 44% / 67% 
MurA1 45% / 70% Enterococcus 
faecalis MurA2 46% / 68% 
MurA1 46% / 70% Clostridium 
tetani MurA2 48% / 70% 
Helicobacter pylori MurA 47% / 69% 
Campylobacter 
jejuni MurA 49% / 73% 
Vibrio vulnificus MurA 78% / 91% 
Mycobacterium 
tuberculosis MurA 43% / 66% 
Escherichia coli MurA 93% / 97% 
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by fosfomycin. Indeed, the sequence alignments do show that these particular gram-
positive MurA enzymes possess the corresponding Cys115 residue.  The outcome of 
the sequence alignments led us to pursue the biochemical characterization of these 
enzymes. The MurA1 and MurA2 genes were amplified by PCR followed by 
restriction digestion and ligation into pGEX-6p-1 vector as described in section 2.4.  
Table 2: Sequence alignments of E. cloacae MurA, S. aureus and B. subtilis MurA1 and MurA2. 
Residues that are identical in all sequences are highlighted and correspond to the loop 
region of E. cloacae MurA (residues 111-122). 
         
                  ....|....|....|....|....|....|....|....|....|....|  
                      5         15        25        35        45     
E.cloacae MurA    --MDKFRVQGPTRLQGEVTISGAKNAALPILFAALLA-EEPVEIQNVPKL  
S.aureus MurA1    --MDKIVIKGGNKLTGEVKVEGAKNAVLPILTASLLASDKPSKLVNVPAL  
S.aureus MurA2    MAQEVIKIRGGRTLNGEVNISGAKNSAVAIIPATLLA-QGHVKLEGLPQI  
B.subtilis MurA1  --MEKIIVRGGQKLNGTVKVEGAKNAVLPVIAASLLASEEKSVICDVPTL  
B.subtilis MurA2  --MEKLNIAGGDSLNGTVHISGAKNSAVALIPATILA-NSEVTIEGLPEI  
 
                  ....|....|....|....|....|....|....|....|....|....|  
                      55        65        75        85        95     
E.cloacae MurA    KDIDTTMKLLTQLGTKVE-RNGS--VWIDASNVNNFSAPYDLVKTMRASI  
S.aureus MurA1    SDVETINNVLTTLNADVTYKKDENAVVVDATKTLNEEAPYEYVSKMRASI  
S.aureus MurA2    SDVKTLVSLLEDLNIKASLNGTE--LEVDTTEIQNAALPNNKVESLRASY  
B.subtilis MurA1  SDVYTINEVLRHLGADVHFENNE--VTVNASYALQTEAPFEYVRKMRASV  
B.subtilis MurA2  SDIETLRDLLKEIGGNVHFENGE--MVVDPTSMISMPLPNGKVKKLRASY 
 
                  ....|....|....|....|....|....|....|....|....|....|  
                      105       115       125       135       145    
E.cloacae MurA    WALGPLVARFGQGQVSLPGGCAIGARPVDLHIFGLEKLGAEIKLEEGYVK  
S.aureus MurA1    LVMGPLLARLGHAIVALPGGCAIGSRPIEQHIKGFEALGAEIHLENGNIY  
S.aureus MurA2    YMMGAMLGRFKKCVIGLPGGCPLGPRPIDQHIKGFKALGAEIDESSTTSM  
B.subtilis MurA1  LVMGPLLARTGHARVALPGGCAIGSRPIDQHLKGFEAMGAEIKVGNGFIE  
B.subtilis MurA2  YLMGAMLGRFKQAVIGLPGGCHLGPRPIDQHIKGFEALGA EVTNEQGAI  
 
                  ....|....|....|....|....|....|....|....|....|....|  
                      155       165       175       185       195 
E.cloacae MurA    ASVNGRLKGAHIVMDKVSVGATVTIMSAATLAEGTTIIENAAREPEIVDT  
S.aureus MurA1    ANAKDGLKGTSIHLDFPSVGATQNIIMAASLAKGKTLIENAAKEPEIVDL  
S.aureus MurA2    KIEAKELKGAHIFLDMVSVGATINIMLAAVYATGQTVIENAAKEPEVVDV  
B.subtilis MurA1  AEVKGRLQGAKIYLDFPSVGATENLIMAAALAEGTTTLENVAKEPEIVDL  
B.subtilis MurA2  YLRAERLRGARIYLDVVSVGATINIMLAAVLAEGKTIIENAAKEPEIIDV  
 
                  ....|....|....|....|....|....|....|....|....|....|  
                      205       215       225       235       245 
E.cloacae MurA    ANFLVALGAKISGQGTDRITIEGVERLGGGVYRVLPDRIETGTFLVAAAI  
S.aureus MurA1    ANYINEMGGRITGAGTDTITINGVESLHGVEHAIIPDRIEAGTLLIAGAI  
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S.aureus MurA2    ANFLTSMGANIKGAGTSTIKINGVKELHGSEYQVIPDRIEAGTYMCIAAA  
B.subtilis MurA1  ANYINGMGGKIRGAGTGTIKIEGVEKLHGVKHHIIPDRIEAGTFMVAAAI  
B.subtilis MurA2  ATLLTSMGAKIKGAGTNVIRIDGVKELHGCKHTIIPDRIEAGTFMIAGAA  
 
                  ....|....|....|....|....|....|....|....|....|....|  
                      255       265       275       285       295 
E.cloacae MurA    SGGKIVCRNAQPDTLDAVLAKLREAGADIETGEDWISLDMHGKRPKAVTV  
S.aureus MurA1    TRGDIFVRGAIKEHMASLVYKLEEMGVELDYQEDGIRVRA EGELQPVDI  
S.aureus MurA2    CGENVILNNIVPKHVETLTAKFSELGVNVDVRDERIRINN NAPYQFVDI  
B.subtilis MurA1  TEGNVLVKGAVPEHLTSLIAKMEEMGVTIKDEGEGLRVIG PKELKPIDI  
B.subtilis MurA2  MGKEVIIDNVIPTHLESLTAKLREMGYHIETSDDQLLIVGGQKNLKPVDV  
  
                 ....|....|....|....|....|....|....|....|....|....|  
                      305       315       325       335       345 
E.cloacae MurA    RTAPHPAFPTDMQAQFTLLNLVAEGTGVITETIFENRFMHVPELIRMGAH  
S.aureus MurA1    KTLPHPGFPTDMQSQMMALLLTANGHKVVTETVFENRFMHVAEFKRMNAN  
S.aureus MurA2    KTLVYPGFATDLQQPITPLLFMANGPSFVTDTIYPERFKHVEELKRMGAN  
B.subtilis MurA1  KTMPHPGFPTDMQSQMMALLLRASGTSMITETVFENRFMHAEEFRRMNGD  
B.subtilis MurA2  KTLVYPGFPTDLQQPMTALLTRAKGTSVVTDTIYSARFKHIDELRRMGAN  
 
                  ....|....|....|....|....|....|....|....|....|....|  
                      355       365       375       385       395 
E.cloacae MurA    AEIESNTVICHGVEKLSGAQVMATDLRASASLVLAGCIAEGTTVVDRIYH  
S.aureus MurA1    INVEGRSAKLEGKSQLQGAQVKATDLRAAAALILAGLVADGKTSVTELTH  
S.aureus MurA2    IEVDEGTATIK-PSTLHGAEVYASDLRAGACLIIAGLIAEGVTTIYNVKH  
B.subtilis MurA1  IKIEGRSVIINGPVQLQGAEVAATDLRAGAALILAGLVAEGHTRVTELKH  
B.subtilis MurA2  MKVEGRSAIITGPVELQGAKVKASDLRAGSCLVVAGLMADGVTEITGLEH  
 
                  ....|....|....|....|....|....|....|....|. 
                      405       415       425       435              
E.cloacae MurA    IDRGYERIEDKLRALGANIERVKGE---------------- 
S.aureus MurA1    LDRGYVDLHGKLKQLGADIERIND----------------- 
S.aureus MurA2    IYRGYTDIVEHLKALGADIWTETV----------------- 
B.subtilis MurA1  LDRGYVDFHQKLAALGADIERVNDESASEQENKEVVSDLNA 
B.subtilis MurA2  IDRGYSSLEKKLEGLGATIWRERMTDEEIEQLQNS------ 
 
 
3.2. Over-expression of S. aureus and B. subtilis MurA 
Induction studies to determine suitable conditions for protein over-expression 
were performed as described in section 2.2.6. The MurA constructs were used to 
transform BL21(DE3), ArcticExpress(DE3), pLysS(DE3) and RIL(DE3) competent 
cell lines.  All cell lines except ArcticExpress(DE3) displayed reasonable levels of 
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over-expression at 37 ˚C, but the over-expression corresponded only to insoluble 
protein. RIL(DE3) and pLysS(DE3) cell lines displayed the highest levels of over-
expression and solubility in all cases when induction studies were repeated with 
incubation temperatures ranging from  13 ˚C  to 20 ˚C post-induction.  In an attempt 
to increase the amount of soluble protein, induction studies were repeated at 18 ˚C 
post-induction with final concentrations of IPTG at 0.5 mM and 1.0 mM and total 
incubation time at 5 h and 24 h.  The highest levels of over-expression and solubility 
for all enzymes were induction with IPTG to a final concentration of 0.5 mM in the 
RIL(DE3) cell line with a 24 h incubation at 18 ˚C post-induction. Using these 
conditions, S. aureus and B. subtilis MurA1 had approximately 60% soluble over-
expression and S. aureus and B. subtilis MurA2 had approximately 10% soluble over-
expression.  
3.3. Purification of S. aureus and B. subtilis MurA and PreScission 
Protein purification of E. 
cloacae MurA was done by 
Huijong Han and purification of 
E. Coli MurB was done by 
Martha Healy-Fried. Purification 
of S. aureus and B. subtilis 
enzymes was done as described 
in section 2.4.9 and PreScission 
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Figure 5: GST chromatographic profile for 
PreScission protease. 
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protease was purified as described in section 2.5.3.  Using these conditions, all 
enzymes were purified to greater than 95% homogeneity. Purification from a 4 L 
culture of each enzyme yielded 50 mg of PreScission, 50 mg of S. aureus and B. 
subtilis MurA1 and less than 5 mg of S. aureus and B. subtilis MurA2.  
Representative SDS-PAGE gels for the MurA purification are shown in Figure 6. 
Representative chromatographic profiles for PreScission are shown in Figure 5, S. 
aureus and B. subtilis MurA1 in Figure 7 and S. aureus and B. subtilis MurA2 in 
Figure 8.   
97. 4 kD 
45. 0 kD 
31. 0 kD 
21. 5 kD 
14. 4 kD 
GST-tagged  
MurA Digested 
MurA 
PreScission 
protease 
A
B C 
PreScission 
GST-tag 
MurA GST-tagged MurA 
Figure 6: Representative MurA (S. 
aureus MurA1) purification SDS-PAGE 
gels.  
 
A) Sample digest  
B) GST purification  
C) Q-Seph purification 
66. 2 kD 
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3.4. Kinetic Analysis of S. aureus and B. subtilis MurA 
Steady-state kinetic characterization of S. aureus and B. subtilis MurA1 and 
MurA2 was performed in parallel experiments with the MurA enzyme from E. 
cloacae.  
 
 
Figure 7: Representative GST (left) and Q-Seph (right) chromatographic profiles for  
S. aureus and B. subtilis MurA1. 
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Figure 8: Representative GST (left) and Resource Q (right) chromatographic profiles for 
S. aureus and B. subtilis MurA2. 
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The pH profiles of S. aureus 
MurA1 and B. subtilis MurA1 
are similar to that of E. cloacae 
MurA (Figure 9, Table 3).  These 
enzymes display higher activities 
between pH 7 and pH 8 with an 
average decrease in activity of 1- 
to 2-fold at pH 6 or pH 9, 
respectively. S. 
aureus MurA1 
appears 
particularly 
effected at lower 
pH, displaying a 15-fold decrease in activity from pH 7 to pH 6. The S. aureus and B. 
subtilis MurA2 enzymes are less affected by changes in the pH. B. subtilis MurA2 
does mimic the behavior of E. cloacae MurA at pH 6, but displayed no loss of 
activity over pH ranging from 7 to 9.  S. aureus MurA2 displayed no loss of activity 
over the entire pH range of 6 to 9. 
The effect of anions and cations on the enzymatic activity of  S. aureus and B. 
subtilis MurA is comparable to their effect on E. cloacae MurA (Table 4 and Figure 
10).  Potassium, sodium and ammonium ions displayed little change in activity 
compared to that observed with no cations present. Calcium ion, however, provided 
Table 3: Specific activities (U/mg) of E. cloacae MurA, S. aureus and B. 
subtilis MurA1 and MurA2 with change in pH. 
Enzyme MES pH 6 MOPS pH 7 HEPES pH 8 TAPS pH 9
E. cloacae MurA 8.78 11.44 11.20 4.31 
S. aureus MurA1 0.04 0.61 0.73 0.27 
S. aureus MurA2 4.43 4.77 4.38 4.31 
B. subtilis MurA1 0.02 0.13 0.13 0.09 
B. subtilis MurA2 0.14 0.26 0.30 0.32 
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Figure 9: pH profile of E. 
cloacae, S. aureus and B. 
subtilis MurA1 and 
MurA2. 
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Figure 10:  Relative activities of E. cloacae MurA, S. aureus and B. subtilis 
MurA1 and MurA2 in the presence of 50mM salt (top) and detergent or 
solvents (bottom). 
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a significant decrease in the activity of all enzymes, in particular S. aureus MurA1 
which displayed a 90 % loss of activity at the lowest concentration tested. In 
comparison, the activity of S. aureus MurA2 and both B. subtilis enzymes decreased 
by 50 % and E. cloacae activity decreased by 30 %. Chloride, acetate and sulfate ions 
displayed little change in activity of all enzymes compared to that observed with no 
anions present.  Changes in the ionic concentration of the assay solution, determined 
that there was little change in activity of the enzymes at the lower concentrations (50 
mM and 100 mM), but a significant loss of activity at higher concentrations (250 
mM).  
The addition of detergents and organic solvents to the assay solutions for S. 
aureus and B. subtilis enzymes resulted in a loss of activity in all cases unlike that of 
E. cloacae MurA which remained mostly unchanged (Table 5 and Figure 10). In the 
presence of 5 and 10% DMSO or glycerol, both MurA1 enzymes and B. subtilis 
MurA2 displayed a slight loss of activity, while S. aureus MurA2 activity decreased 
30%.  Enzymatic activity of MurA1 and MurA2 for S. aureus and B. subtilis assayed 
with 5 % EtOH, decreased 35% and 15%, respectively, with higher activity loss in the 
presence of 10 % EtOH.  Triton decreased enzymatic activity by over 40% in all 
enzymes, with S. aureus MurA1 noticeably having the largest loss. Enzymatic 
activity of MurA2 for S. aureus and B. subtilis MurA1 and MurA2 assayed with 5 % 
n-Octyl-β-D-glucoside, decreased 80% and 30%, respectively, with higher activity 
loss in the presence of 10 % glucoside.    
 
 49
S. aureus and B. subtilis MurA enzymes display normal saturation behavior when 
the specific activities (U/mg) are plotted as a function of substrate concentration  
(Figure 11).  The kinetic constants derived from these graphs (Table 6) demonstrate 
that the affinity for both substrates (UNAG and PEP) is generally lower than that of 
E. cloacae.  S. aureus MurA2 and B. subtilis MurA2, however, did display Km 
constants for UNAG which were 2-fold higher than that of E. cloacae.  The catalytic 
efficiency (kcat/Km) for all of the enzymes is lower in comparison to E. cloacae 
MurA, however, S. aureus MurA2 is only slightly lower than E. cloacae MurA where 
the remaining enzymes were more than 100-fold lower.  All enzymes were inhibited 
by the antibiotic fosfomycin but none were as sensitive as E. cloacae MurA (Figure 
12).  
Table 6: Kinetic parameters for E. cloacae MurA, S. aureus and B. subtilis MurA1 and 
MurA2. 
Enzyme 
Km 
UNAG 
(mM) 
Vmax 
UNAG 
(U/mg) 
kcat/Km 
UNAG 
(M-1s-1) 
Km PEP 
(mM) 
Vmax PEP 
(U/mg) 
kcat/Km 
PEP 
(M-1s-1) 
IC50 
FOS 
(µM) 
E. cloacae 
MurA 
0.081 
±0.02 
5.3 
±0.2 6.0E+03 
0.016 
±0.004 
6.8 
±0.3 3.9E+04 
1.04 
±0.05 
S. aureus 
MurA1 
0.38 
±0.03 
1.3 
±0.04 1.2E+01 
0.063 
±0.01 
1.3 
±0.04 7.0E+01 
62 
±10 
S. aureus 
MurA2 
0.042 
±0.01 
4.3 
±0.2 5.2E+03 
0.033 
±0.004 
4.1 
±0.1 6.2E+03 
12 
±0.8 
B. subtilis 
MurA1 
0.23 
±0.02 
0.48 
±0.01 6.9E+00 
0.066 
±0.01 
0.49 
±0.02 2.5E+01 
3.8 
±0.9 
B. subtilis 
MurA2 
0.043 
±0.01 
0.17 
±0.01 2.0E+01 
0.017 
±0.002 
0.21 
±0.01 6.3E+01 
220 
±200 
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Figure 11:  Comparison of the steady-state kinetics of E. 
cloacae MurA, S. aureus and B. subtilis MurA1 and 
MurA2.  Enzymatic assays with 6 mM UNAG (top) or 4 mM 
PEP (bottom) and increasing concentrations of the second 
substrate.  All data were fit to equation 1 yielding the kinetic 
parameters shown in Table 6. 
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Figure 12:  Inhibition of E. cloacae MurA, S. aureus and B. subtilis MurA1 and MurA2 
by fosfomycin.  IC50 values of fosfomycin inhibition were determined using 1 mM UNAG 
(left) and 43μM UNAG (right), 1 mM PEP and increasing concentrations of fosfomycin.  
All data were fit to equation 2 yielding the kinetic parameters shown in Table 6. 
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While none of the enzymes were catalytically as efficient as E. cloacae MurA, 
the MurA2 enzymes in both organisms are clearly more efficient than the MurA1 
enzymes, which supports what was found for the S. pneumoniae MurA1 and MurA2 
enzymes previously studied [34]. Structural analysis would be beneficial in 
determining why the kinetic data for S. aureus and B. subtilis MurA1 and MurA2 
enzymes are substantially different than for E. cloacae MurA. Of more interest may 
be what structural differences cause the MurA2 enzyme to be more active than the 
MurA1 enzyme as well as determining fosfomycin potency and substrate binding 
capabilities.  
3.5. Future Analysis 
To continue to obtain a better understanding of the S. aureus and B. subtilis MurA 
enzymes, further work needs to be completed. Experiments should be continued with 
the MurA2 enzymes in an attempt to increase the amount of soluble protein. 
Utilization of an alternate tagged vector system or refolding experiments could 
enhance solubility.  The addition of the charged amino acids, L-Arg and L-Glu, at a 
final concentration of 50 mM in the extraction buffer, has been shown to increase the 
maximum achievable concentration of soluble protein while preventing protein 
aggregation and precipitation [38] which happens to be another problem to be 
investigated.  These enzymes do not concentrate well, which leads to difficulty in 
trying to obtain a high enough enzyme concentration for kinetic assays and 
crystallization trials.  Attempts were made to crystallize S. aureus MurA1 using 
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numerous crystallization buffers, however, no crystals were formed. Aggregation or 
the formation of oligomers in these proteins is suspected as being a concern based on 
preliminary gel filtration experiments using FPLC. Trials were done on several sizes 
of gel filtration column, however, the enzyme consistently eluted in the void volume 
of the column. In addition, determination of protein size using native protein gel 
electrophoresis was not effective. 
Following the development of a more refined protocol to produce these enzymes, 
a structural study should be performed. To date, no crystal structures for any gram-
positive MurA enzyme have been solved.  Doing so will reveal the variations of the 
gram-positive MurA active sites from those that are known for other species. Based 
on this structural information and the kinetic data shown in this thesis, the discovery 
of novel antibiotics targeting MurA may not be far away.  
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4. Conclusions 
 
Sequence analysis of S. aureus and B. subtilis MurA1 and MurA2 indicates that 
all genes are complete and that the enzymes contain the important catalytic residues 
previously identified in E. cloacae MurA.  To demonstrate that these genes encode 
active enzymes, they were each over-expressed and purified.  Kinetic characterization 
revealed that the enzymes from both organisms are active and can catalyze the 
reaction between UNAG and PEP to give EP-UNAG and Pi.  For B. subtilis MurA1 
and MurA2, the enzymes have higher Kms for their substrates and lower kcats than E. 
cloacae MurA suggesting that, at a kinetic level, MurA1 more closely resembles 
MurA2 than its gram-negative counterpart.  That does not seem to be the case for the 
S. aureus MurA enzymes, since MurA1 in this organism is kinetically more similar to 
E. cloacae MurA. In any case, inhibitor design would have to possess activity against 
both MurA1 and MurA2 to ensure antibacterial activity against gram-positive 
pathogens. 
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